Researchers find new way to target blood stem cell cancers

January 25, 2017
Microscopic image of a leukemia cancer stem cell with DNA colored in blue and the identifying surface marker CD99 colored in green. Credit: Montreh Tavakkoli

A protein-sugar molecule, CD99, occurs more frequently than normal on stem cells responsible for blood cancers, including acute myeloid leukemia (AML) and the related myelodysplastic syndromes (MDS).

This is the finding of a study led by researchers from NYU Langone Medical Center and Memorial Sloan Kettering Cancer Center, and published online Jan. 25 in Science Translational Medicine.

Building on this discovery, the study authors designed an antibody that recognizes and destroys CD99-covered leukemia cells while sparing normal blood , a finding confirmed by experiments in and in mice with AML cells. Antibodies are immune system proteins that stick to a specific target, like a protein on the surface of invading bacterium. In recent years, researchers have become capable of engineering antibodies so that they target disease-related molecules.

"Our findings not only identify a new molecule expressed on stem cells that drive these human malignancies, but we show that antibodies against this target can directly kill human AML stem cells," says corresponding study author, Christopher Y. Park, MD, PhD, associate professor in the Department of Pathology at NYU Langone and its Perlmutter Cancer Center.

"While we still have important details to work out, CD99 is likely to be an exploitable therapeutic target for most AML and MDS patients, and we are working urgently to finalize a therapy for human testing," says Park.

Direct Cell Killing

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) arise from abnormal stem cells that build up in bone marrow until they interfere with normal blood cell production. Patients struggle with anemia, increased risk for infection, and bleeding.

The study results are based on the understanding that cancers, like normal tissues, contain stem cells that give rise to all the other cells. Such "cancer stem cells" are known to be major drivers of many cancer types. In AML, a small group of become incapable of maturing into red or as intended. Most leukemias respond initially to standard treatment, but relapse is common as standard treatments fail to kill , which continue to multiply.

The research team became interested in CD99 when they observed that it occurs frequently on AML and MDS cells, and then noted in the literature that CD99 is elevated in a rare bone cancer called Ewing's Sarcoma. This prompted them to see if CD99 was important in the development of these blood diseases.

When researchers examined stem cell populations from 79 AML and 24 MDS patients, they found that approximately 85 percent of stem cells in both groups expressed high levels of CD99. The levels were so high that diseased stem cells could be cleanly separated from related, normal stem cells in AML patients.

Upon confirming that CD99 was abundant on leukemia stem cells, the research team then made several CD99 antibodies, and chose to focus on the one that most effectively killed those cells. Researchers found that when the study antibody attaches itself to CD99 on the surface of a , it sends a signal inside the cell that increases the activity of enzymes called SRC-family kinases.

While the team does not yet know why, the binding of their antibody to CD99, and the subsequent activation of these enzymes, causes leukemia stem cells to die. Most cells with genetic mistakes leading to cancer "sense" they are flawed and self-destruct, but CD99, so the theory goes, may be part of a mechanism that prevents this. As the antibody binds to CD99, it appears to undo this block on self-destruction.

"With the appropriate support, we believe we can rapidly determine the best antibodies for use in patients, produce them at the quality needed to verify our results, and apply for permission to begin clinical trials," says Park.

While the most common acute leukemia affecting adults (22,000 new cases each year) and expected to become more prevalent as the population ages, AML it is still relatively rare, accounting for 1.2 percent of U.S. cancer deaths. About 15,000 mostly elderly patients are diagnosed with MDS each year as well.

Explore further: Screening drugs to kill cancer cells in their safe spaces

More information: "CD99 is a therapeutic target on disease stem cells in myeloid malignancies," Science Translational Medicine stm.sciencemag.org/lookup/doi/ … scitranslmed.aaj2025

Related Stories

Screening drugs to kill cancer cells in their safe spaces

October 31, 2016
Existing chemotherapy approaches treat cancer by targeting cells that are actively multiplying and have a high metabolic rate. However, cancer stem cells can escape this targeting, leading to chemotherapy-resistant cancer ...

Bone marrow inflammation predicts leukemia risk

October 3, 2016
Cancer is generally thought to arise from genetic damage within individual cells, but recent evidence has suggested that abnormal signaling in the surrounding tissue also plays an important role. In a study published September ...

Antibodies directed against cancer stem cells could help patients with acute myeloid leukemia

September 23, 2016
An antibody drug that targets a surface marker on cancer stem cells could offer a promising new therapeutic approach for treating acute myeloid leukemia (AML), a form of blood cancer that affects an estimated 50,000 people ...

As leukemia evolves, stem cells hold keys to newer therapies

August 30, 2016
A recent study by University of Rochester Medical Center researchers proves why leukemia is so difficult to treat and suggests that the current approach to drug development should be adjusted to target a broader range of ...

Inhibiting CDK6 prevents leukemic relapse

January 27, 2015
Despite enormous progress in cancer therapy, many patients still relapse because their treatment addresses the symptoms of the disease rather than the cause, the so-called stem cells. Work in the group of Veronika Sexl at ...

Recommended for you

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.